A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell LinesSochaj-Gregorczyk, Alicja M.; Serwotka-Suszczak, Anna M.; Otlewski, JacekJournal of Immunotherapy: July/August 2016 - Volume 39 - Issue 6 - p 223–232 doi: 10.1097/CJI.0000000000000125 Basic Study Abstract In Brief Author InformationAuthors Article MetricsMetrics Targeted therapy is a new type of cancer treatment that most often uses biologically active drugs attached to a monoclonal antibody. This so called antibody-drug conjugate strategy allows the use of highly toxic substances that target tumor cells specifically, leaving healthy tissues largely unaffected. Over the last few years, antibody-drug conjugates have become a powerful tool in cancer treatment. We developed and characterized a novel cytotoxic conjugate against HER2+ tumors in which the antibody has been substituted with a much smaller molecule: the affibody. The conjugate is composed of the ZHER2:2891 affibody that recognizes HER2 and a highly potent cytotoxic drug auristatin E. The ZHER2:2891 molecule does not contain cysteine(s) in its amino acid sequence. We generated 3 variants of ZHER2:2891, each containing a single cysteine to allow conjugation through the maleimide group that is present in the cytotoxic component. In 2 variants, we introduced single S46C and D53C substitutions. In the third variant, a short Drug Conjugation Sequence (DCS) containing a single cysteine was introduced at the C-terminus of ZHER2:2891, resulting in ZHER2:2891-DCS. The latter variant exhibited a significantly higher conjugation yield, and therefore its cytotoxicity has been studied more thoroughly. The ZHER2:2891-DCS-MMAE conjugate killed the HER2-overexpressing SK-BR-3 and MDA-MB-453 cells efficiently (IC50 values of 5.2 and 24.8 nM, respectively). The T-47-D and MDA-MB-231 cells that express normal levels of HER2 were significantly less sensitive to the conjugate (IC50 values of 135.6 and 161.5 nM, respectively). Overall, we have demonstrated for the first time that proteins other than antibodies/antibody fragments can be successfully combined with a linker-drug module, resulting in conjugates that eliminate cancer cells selectively. Supplemental Digital Content is available in the text. Department of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, Wroclaw, Poland Reprints: Alicja M. Sochaj-Gregorczyk, Department of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, Joliot-Curie 14a, 50-383 Wroclaw, Poland (e-mails: firstname.lastname@example.org; email@example.com). Received December 22, 2015 Accepted March 29, 2016 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.